LifeLink Ventures

The firm focuses on seed and Series A rounds where the science is de-risked enough to demonstrate a technical edge but early enough to capture step-change returns. Follow-on capacity is reserved for portfolio companies hitting clinical or validation milestones, reflecting a conviction-concentration model rather than an index approach.

Offices in Menlo Park and Boston flank the core US biotech corridors, while Manchester and Luxembourg provide operational entry points into the UK's Golden Triangle and continental European innovation clusters. This layout supports cross-border syndicate formation and helps portfolio companies pursue parallel FDA and EMA regulatory strategies.

LifeLink's mandate sits at the intersection of biology and computation. The firm evaluates therapeutic platforms, AI-enabled diagnostics, and computational biology tools, but does not typically invest in therapeutics alone without a technology layer. Its portfolio reflects this filter — companies where IP resides in both the model and the biologic.

Yes. LifeLink regularly syndicates with specialist biotech funds, university venture arms, and other family offices running concentrated life-science mandates. The firm's Luxembourg presence also facilitates European investor syndication structures.

Unlike traditional VC funds constrained by 10-year cycles, LifeLink can hold positions through Phase II or Phase III clinical readouts. This flexibility is a direct function of its family-office architecture and is the reason it attracts founders unwilling to compromise long-term clinical vision for fund-life pressure.